RP2 + Ipilimumab + Nivolumab
Phase 2/3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Uveal Melanoma
Conditions
Metastatic Uveal Melanoma
Trial Timeline
Dec 17, 2024 → Oct 1, 2031
NCT ID
NCT06581406About RP2 + Ipilimumab + Nivolumab
RP2 + Ipilimumab + Nivolumab is a phase 2/3 stage product being developed by Replimune for Metastatic Uveal Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06581406. Target conditions include Metastatic Uveal Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Uveal Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
15
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06581406 | Phase 2/3 | Recruiting |
Competing Products
20 competing products in Metastatic Uveal Melanoma